Cytokine and Angiogenesis Inhibitors

  • Simon Chowdhury
  • Martin Gore
  • Timothy G. Eisen


Renal cell carcinoma is an important malignancy accounting for approximately 3% of all adult cancers [1]. The incidence of renal cell carcinoma has been steadily and significantly increasing over the past two decades, with worldwide mortality expected to exceed 100,000 [2]. A significant proportion of patients with localized disease can be cured by nephrectomy; however, at presentation approximately 50% of patients have locally advanced or metastatic disease [3]. The outlook for these patients remains poor, with a 5-year survival of less than 10% [2].


Renal Cell Carcinoma Clin Oncol Metastatic Renal Cell Carcinoma Angiogenesis Inhibitor Advanced Renal Cell Carcinoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Jemal A, et al. Cancer statistics, 2002. CA Cancer J Clin 2002;52(1):23–47.PubMedGoogle Scholar
  2. 2.
    Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med 1996;335(12):865–875.PubMedCrossRefGoogle Scholar
  3. 3.
    Dhote R, et al. Risk factors for adult renal cell carcinoma: a systematic review and implications for prevention. BJU Int 2000;86(1):20–27.PubMedCrossRefGoogle Scholar
  4. 4.
    Yagoda A, Abi-Rached B, Petrylak D. Chemotherapy for advanced renal-cell carcinoma: 1983–1993. Semin Oncol 1995;22(1):42–60.PubMedGoogle Scholar
  5. 5.
    Elson PJ, Witte RS, Trump DL. Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res 1988;48(24 pt 1):7310–7313.PubMedGoogle Scholar
  6. 6.
    Palmer PA, et al. Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2. Ann Oncol 1992;3(6):475–480.PubMedGoogle Scholar
  7. 7.
    Jones M, et al. The impact of interleukin-2 on survival in renal cancer: a multivariate analysis. Cancer Biother 1993;8(4):275–288.PubMedGoogle Scholar
  8. 8.
    Fossa SD, Kramar A, Droz JP. Prognostic factors and survival in patients with metastatic renal cell carcinoma treated with chemotherapy or interferon-alpha. Eur J Cancer 1994;30A(9):1310–1314.PubMedCrossRefGoogle Scholar
  9. 9.
    Motzer RJ, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999;17(8):2530–2540.PubMedGoogle Scholar
  10. 10.
    Motzer RJ, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 2004;22(3):454–463.PubMedCrossRefGoogle Scholar
  11. 11.
    Motzer RJ, et al. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol 2002;20(9):2376–2381.PubMedCrossRefGoogle Scholar
  12. 12.
    Kudoh S, et al. Defective granzyme B gene expression and lytic response in T lymphocytes infiltrating human renal cell carcinoma. J Immunother 1997;20(6):479–487.PubMedCrossRefGoogle Scholar
  13. 13.
    Ulchaker J, et al. Interferon-gamma production by T lymphocytes from renal cell carcinoma patients: evidence of impaired secretion in response to interleukin-12. J Immunother 1999;22(1):71–79.PubMedCrossRefGoogle Scholar
  14. 14.
    Almand B, et al. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 2001;166(1):678–689.PubMedGoogle Scholar
  15. 15.
    Finke JH, et al. Tumor-infiltrating lymphocytes in patients with renal-cell carcinoma. Ann N Y Acad Sci 1988;532:387–394.PubMedCrossRefGoogle Scholar
  16. 16.
    Van Den Eynde BJ, et al. A new antigen recognized by cytolytic T lymphocytes on a human kidney tumor results from reverse strand transcription. J Exp Med 1999;190(12):1793–1800.CrossRefGoogle Scholar
  17. 17.
    Motzer RJ, et al. Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma. J Clin Oncol 2000;18(9):1928–1935.PubMedGoogle Scholar
  18. 18.
    Negrier S, et al. Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francais d’Immunotherapie. Ann Oncol 2002;13(9):1460–1468.PubMedCrossRefGoogle Scholar
  19. 19.
    Van Poppel H, Baert L. Nephrectomy for metastatic renal cell carcinoma and surgery for distant metastases. Acta Urol Belg 1996;64(2):11–17.PubMedGoogle Scholar
  20. 20.
    Piltz S, et al. Long-term results after pulmonary resection of renal cell carcinoma metastases. Ann Thorac Surg 2002;73(4):1082–1087.PubMedCrossRefGoogle Scholar
  21. 21.
    Le Francois D, et al. Evolution of cell-mediated immunity in mice bearing tumors produced by a mammary carcinoma cell line. Influence of tumor growth, surgical removal, and treatment with irradiated tumor cells. J Natl Cancer Inst 1971;46(5):981–987.PubMedGoogle Scholar
  22. 22.
    Whitney RB, Levy JG, Smith AG. Influence of tumor size and surgical resection on cell-mediated immunity in mice. J Natl Cancer Inst 1974;53(1):111–116.PubMedGoogle Scholar
  23. 23.
    Dadian G, et al. Immunological parameters in peripheral blood of patients with renal cell carcinoma before and after nephrectomy. Br J Urol 1994;74(1):15–22.PubMedCrossRefGoogle Scholar
  24. 24.
    Pantuck AZA, Shvarts O, Gitlitz B, deKernion J, Figlin R, Belldegrun A. Natural history and the role of nephrectomy in the biology of RCC: the UCLA experience. Proc Am Soc Clin Oncol 2000;19:1348.Google Scholar
  25. 25.
    Flanigan RC, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001;345(23):1655–1659.PubMedCrossRefGoogle Scholar
  26. 26.
    Mickisch GH, et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001;358(9286):966–970.PubMedCrossRefGoogle Scholar
  27. 27.
    Flanigan RC, et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 2004;171(3):1071–1076.PubMedCrossRefGoogle Scholar
  28. 28.
    Naitoh J, et al. Metastatic renal cell carcinoma with concurrent inferior vena caval invasion: long-term survival after combination therapy with radical nephrectomy, vena caval thrombectomy and postoperative immunotherapy. J Urol 1999;162(1):46–50.PubMedCrossRefGoogle Scholar
  29. 29.
    Lineham WM, et al. Cancer of the kidney and ureter. In: Devita VT, ed. Cancer: Principles and Practice of Oncology. Philadephia: Lippincott Williams and Wilkins, 1997:1271–1300.Google Scholar
  30. 30.
    Motzer RJ, et al. Phase II trial of branched peg interferon-alpha 2a (40 kDa) for patients with advanced renal cell carcinoma. Ann Oncol 2002;13(11):1799–1805.PubMedCrossRefGoogle Scholar
  31. 31.
    Bukowski, R, et al. Pegylated interferon alfa-2b treatment for patients with solid tumors: a phase I/II study. J Clin Oncol 2002;20(18):3841–3849.PubMedCrossRefGoogle Scholar
  32. 32.
    Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators. Lancet 1999;353(9146):14–17.Google Scholar
  33. 33.
    Hancock B, Griffiths G, Ritchie A, et al., on behalf of the MRC Renal Cancer Collaborators.Updated results of the MRC randomised controlled trial of alpha interferon vs. MPA in patients with metastatic renal carcinoma. Proc Am Soc Clin Oncol 2000;abstract 1336.Google Scholar
  34. 34.
    Coppin C, et al. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2000(3):CD001425.Google Scholar
  35. 35.
    Hoffman AD, et al. Expression of retinoic acid receptor beta in human renal cell carcinomas correlates with sensitivity to the antiproliferative effects of 13-cis-retinoic acid. Clin Cancer Res 1996;2(6):1077–1082.PubMedGoogle Scholar
  36. 36.
    Motzer RJ, et al. Interferon alfa-2a and 13-cis-retinoic acid in renal cell carcinoma: antitumor activity in a phase II trial and interactions in vitro. J Clin Oncol 1995;13(8):1950–1957.PubMedGoogle Scholar
  37. 37.
    Motzer RJ, et al. Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol 2000;18(16):2972–2980.PubMedGoogle Scholar
  38. 38.
    Gleave ME, et al. Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group. N Engl J Med 1998;338(18):1265–1271.PubMedCrossRefGoogle Scholar
  39. 39.
    De Mulder PH, et al. EORTC (30885) randomised phase III study with recombinant interferon alpha and recombinant interferon alpha and gamma in patients with advanced renal cell carcinoma. The EORTC Genitourinary Group. Br J Cancer 1995;71(2):371–375.PubMedGoogle Scholar
  40. 40.
    Fyfe G, et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995;13(3):688–696.PubMedGoogle Scholar
  41. 41.
    Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 2000;6(suppl 1):S55–57.PubMedGoogle Scholar
  42. 42.
    Yang JC, et al. Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report. J Clin Oncol 1994;12(8):1572–1576.PubMedGoogle Scholar
  43. 43.
    Yang JC, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003;21(16):3127–3132.PubMedCrossRefGoogle Scholar
  44. 44.
    Bukowski RM. Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2. Cancer 1997;80(7):1198–1220.PubMedCrossRefGoogle Scholar
  45. 45.
    Lindsey KR, Rosenberg SA, Sherry RM. Impact of the number of treatment courses on the clinical response of patients who receive high-dose bolus interleukin-2. J Clin Oncol 2000;18(9):1954–1959.PubMedGoogle Scholar
  46. 46.
    Rosenberg SA, et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst 1993;85(8):622–632.PubMedCrossRefGoogle Scholar
  47. 47.
    Figlin RA, et al. Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CD8(+) selected tumor infiltrating lymphocytes from primary tumor. J Urol 1997;158(3 Pt 1):740–745.PubMedGoogle Scholar
  48. 48.
    Figlin RA, et al. Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. J Clin Oncol 1999;17(8):2521–2529.PubMedGoogle Scholar
  49. 49.
    Sherry RM, Rosenberg SA, Yang JC. Relapse after response to interleukin-2-based immunotherapy: patterns of progression and response to retreatment. J Immunother 1991;10(5):371–375.PubMedCrossRefGoogle Scholar
  50. 50.
    Negrier S, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d’Immunotherapie. N Engl J Med 1998;338(18):1272–1278.PubMedCrossRefGoogle Scholar
  51. 51.
    Escudier B, et al. Cytokines in metastatic renal cell carcinoma: is it useful to switch to interleukin-2 or interferon after failure of a first treatment? Groupe Francais d’Immunotherape. J Clin Oncol 1999;17(7):2039–2043.PubMedGoogle Scholar
  52. 52.
    Motzer RJ, et al. Randomized multicenter phase II trial of subcutaneous recombinant human interleukin-12 versus interferon-alpha 2a for patients with advanced renal cell carcinoma. J Interferon Cytokine Res 2001;21(4):257–263.PubMedCrossRefGoogle Scholar
  53. 53.
    Lissoni P, et al. In vivo stimulation of IL-12 secretion by subcutaneous low-dose IL-2 in metastatic cancer patients. Br J Cancer 1998;77(11):1957–1960.PubMedGoogle Scholar
  54. 54.
    Pyrhonen S, et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 1999;17(9):2859–2867.PubMedGoogle Scholar
  55. 55.
    Fossa SD, et al. Recombinant interferon alfa-2a with or without vinblastine in metastatic renal cell carcinoma: results of a European multi-center phase III study. Ann Oncol 1992;3(4):301–305.PubMedGoogle Scholar
  56. 56.
    Murphy BR, et al. A phase II trial of interferon alpha-2A plus fluorouracil in advanced renal cell carcinoma. A Hoosier Oncology Group study. Invest New Drugs 1992;10(3):225–230.PubMedCrossRefGoogle Scholar
  57. 57.
    Atzpodien J, et al. Interleukin-2 in combination with interferonalpha and 5-fluorouracil for metastatic renal cell cancer. Eur J Cancer 1993;29A(suppl 5):S6–8.PubMedCrossRefGoogle Scholar
  58. 58.
    Atzpodien J, et al. IL-2 in combination with IFN-alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial. Br J Cancer 2001;85(8):1130–1136.PubMedCrossRefGoogle Scholar
  59. 59.
    Hofmockel G, et al. Immunochemotherapy for metastatic renal cell carcinoma using a regimen of interleukin-2, interferon-alpha and 5-fluorouracil. J Urol 1996;156(1):18–21.PubMedCrossRefGoogle Scholar
  60. 60.
    Joffe JK, et al. A phase II study of interferon-alpha, interleukin-2 and 5-fluorouracil in advanced renal carcinoma: clinical data and laboratory evidence of protease activation. Br J Urol 1996;77(5):638–649.PubMedGoogle Scholar
  61. 61.
    Ellerhorst JA, et al. Phase II trial of 5-fluorouracil, interferon-alpha and continuous infusion interleukin-2 for patients with metastatic renal cell carcinoma. Cancer 1997;80(11):2128–2132.PubMedCrossRefGoogle Scholar
  62. 62.
    Tourani JM, et al. Outpatient treatment with subcutaneous interleukin-2 and interferon alfa administration in combination with fluorouracil in patients with metastatic renal cell carcinoma: results of a sequential nonrandomized phase II study. Subcutaneous Administration Proleukin Program Cooperative Group. J Clin Oncol 1998;16(7):2505–2513.PubMedGoogle Scholar
  63. 63.
    Elias L, et al. Infusional interleukin-2 and 5-fluorouracil with subcutaneous interferon-alpha for the treatment of patients with advanced renal cell carcinoma: a southwest oncology group Phase II study. Cancer 2000;89(3):597–603.PubMedCrossRefGoogle Scholar
  64. 64.
    Ravaud A, et al. Subcutaneous interleukin-2, interferon alfa-2a, and continuous infusion of fluorouracil in metastatic renal cell carcinoma: a multicenter phase II trial. Groupe Francais d’Immunotherapie. J Clin Oncol 1998;16(8):2728–2732.PubMedGoogle Scholar
  65. 65.
    Negrier S, et al. Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. Groupe Francais d’Immunotherapie, Federation Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol 2000;18(24):4009–4015.PubMedGoogle Scholar
  66. 66.
    Smith IE, et al. High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer. J Clin Oncol 1995;13(2):424–429.PubMedGoogle Scholar
  67. 67.
    Ahmed FMP, Macfarlane V, Gore M. Infusional chemotherapy (cisplatin, epirubicin, 5-FU: ECF) for patients with epithelial ovarian carcinoma. In: 9th NCI-EORTC Symposium on New Drug Therapy, 1996, Amsterdam.Google Scholar
  68. 68.
    Allen MJ, et al. Protracted venous infusion 5-fluorouracil in combination with subcutaneous interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer: a phase II study. Br J Cancer 2000;83(8):980–985.PubMedCrossRefGoogle Scholar
  69. 69.
    Oevermann K, et al. Capecitabine in the treatment of metastatic renal cell carcinoma. Br J Cancer 2000;83(5):583–587.PubMedCrossRefGoogle Scholar
  70. 70.
    Porzsolt F. Adjuvant therapy of renal cell carcinoma with interferon alpha-2a. Proc Am Soc Clin Oncol 1992;11:622.Google Scholar
  71. 71.
    Trump DL, Elson P, Propert K, et al. Randomized, controlled trial of adjuvant therapy with lymphoblastoid interferon (L-IFN) in resected, high-risk renal cell carcinoma (HR-RCC) Proc Am Soc Clin Oncol 1966;15:253.Google Scholar
  72. 72.
    Pizzocaro G, et al. Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study. J Clin Oncol 2001;19(2):425–431.PubMedGoogle Scholar
  73. 73.
    Clark JI, et al. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. J Clin Oncol 2003;21(16):3133–3140.PubMedCrossRefGoogle Scholar
  74. 74.
    Folkman J. Antiangiogenic therapy. In: Devita VT, ed. Cancer: Principles and Practice of Oncology. Philadephia: Lippincott Williams and Wilkins, 1997.Google Scholar
  75. 75.
    Modzelewski RA, et al. Isolation and identification of fresh tumorderived endothelial cells from a murine RIF-1 fibrosarcoma. Cancer Res 1994;54(2):336–339.PubMedGoogle Scholar
  76. 76.
    Kato T, et al. Enhanced suppression of tumor growth by combination of angiogenesis inhibitor O-(chloroacetyl-carbamoyl)fumagillol (TNP-470) and cytotoxic agents in mice. Cancer Res 1994;54(19):5143–5147.PubMedGoogle Scholar
  77. 77.
    Teicher BA, et al. Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents. Int J Cancer 1994;57(6):920–925.PubMedCrossRefGoogle Scholar
  78. 78.
    Ingber D, et al. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 1990;348(6301):555–557.PubMedCrossRefGoogle Scholar
  79. 79.
    Stadler WM, et al. Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal carcinoma. J Clin Oncol 1999;17(8):2541–2545.PubMedGoogle Scholar
  80. 80.
    George DJ, Kaelin WG Jr. The von Hippel-Lindau protein, vascular endothelial growth factor, and kidney cancer. N Engl J Med 2003;349(5):419–421.PubMedCrossRefGoogle Scholar
  81. 81.
    Yang JC, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349(5):427–434.PubMedCrossRefGoogle Scholar
  82. 82.
    Rosen L, Mulay M, Mayers A, et al. Phase I dose-escalating trial of SU5416, a novel angiogenesis inhibitor in patients with advanced malignancies (meeting abstract). Proc Am Soc Clin Oncol 1999;18:618.Google Scholar
  83. 83.
    Kuenen BC, et al. Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma. Clin Cancer Res 2003;9(5):1648–1655.PubMedGoogle Scholar
  84. 84.
    Gingras D, et al. Matrix proteinase inhibition by AE-941, a multifunctional antiangiogenic compound. Anticancer Res 2001;21(1A):145–155.PubMedGoogle Scholar
  85. 85.
    Batist G, et al. Neovastat (AE-941) in refractory renal cell carcinoma patients: report of a phase II trial with two dose levels. Ann Oncol 2002;13(8):1259–1263.PubMedCrossRefGoogle Scholar
  86. 86.
    O’Reilly MS, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994;79(2):315–328.PubMedCrossRefGoogle Scholar
  87. 87.
    O’Reilly MS, et al. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 1996;2(6):689–692.PubMedCrossRefGoogle Scholar
  88. 88.
    O’Reilly MS, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88(2):277–285.PubMedCrossRefGoogle Scholar
  89. 89.
    Herbst RS, et al. Phase I study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 2002;20(18):3792–3803.PubMedCrossRefGoogle Scholar
  90. 90.
    Eisen T, et al. Continuous low dose thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br J Cancer 2000;82(4):812–817.PubMedCrossRefGoogle Scholar
  91. 91.
    Stebbing J, et al. The treatment of advanced renal cell cancer with high-dose oral thalidomide. Br J Cancer 2001;85(7):953–958.PubMedCrossRefGoogle Scholar
  92. 92.
    Motzer RJ, et al. Phase II trial of thalidomide for patients with advanced renal cell carcinoma. J Clin Oncol 2002;20(1):302–306.PubMedCrossRefGoogle Scholar
  93. 93.
    Minor DR, et al. A phase II study of thalidomide in advanced metastatic renal cell carcinoma. Invest New Drugs 2002;20(4):389–393.PubMedCrossRefGoogle Scholar
  94. 94.
    Escudier B, et al. Phase II trial of thalidomide in renal-cell carcinoma. Ann Oncol 2002;13(7):1029–1035.PubMedCrossRefGoogle Scholar
  95. 95.
    Daliani DD, et al. A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma. Cancer 2002;95(4):758–765.PubMedCrossRefGoogle Scholar
  96. 96.
    Corral LG, et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 1999;163(1):380–386.PubMedGoogle Scholar
  97. 97.
    Richardson PG, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002;100(9):3063–3067.PubMedCrossRefGoogle Scholar
  98. 98.
    Nathan PD, Gore ME, Eisen TG. Unexpected toxicity of combination thalidomide and interferon alpha-2a treatment in metastatic renal cell carcinoma. J Clin Oncol 2002;20(5):1429–1430.PubMedGoogle Scholar
  99. 99.
    Hernberg M, et al. Interferon alfa-2b three times daily and thalidomide in the treatment of metastatic renal cell carcinoma. J Clin Oncol 2003;21(20):3770–3776.PubMedCrossRefGoogle Scholar
  100. 100.
    Amato R, Schell J, Thompson N, Moore R, Miles B. Phase II study of thalidomide and interleukin-2 in patients with metastatic renal cell carcinoma. Proc Am Soc Clin Oncol 2003;abstract 1556.Google Scholar

Copyright information

© Springer-Verlag London Limited 2007

Authors and Affiliations

  • Simon Chowdhury
    • 1
  • Martin Gore
    • 2
  • Timothy G. Eisen
    • 3
  1. 1.Department of MedicineRoyal Marsden HospitalLondonUK
  2. 2.Department of Medical OncologyRoyal Marsden HospitalLondonUK
  3. 3.Renal, Melanoma and Lung Units Department of MedicineRoyal Marsden HospitalLondonUK

Personalised recommendations